Change in mean glucose may be a better metric for measuring the efficacy of diabetes interventions than HbA1c, time in range and time above range, according to a speaker. At the International Conference on Advanced Technologies & Treatments for Diabetes, David Rodbard, MD, president and chief scientific officer for Biomedical Informatics Consultants LLC in Potomac, Maryland, analyzed correlations between…
Read more
CGM metrics may be better for determining diabetes intervention efficacy than HbA1c





